Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals
- PMID: 25687450
- PMCID: PMC4387111
- DOI: 10.1016/j.nucmedbio.2014.12.011
Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals
Abstract
Introduction: The heavy halogen (211)At is of great interest for targeted radiotherapy because it decays by the emission of short-range, high-energy α-particles. However, many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking other (211)At labeling strategies. One relatively unexplored approach is to utilize prosthetic groups based on astatinated rhodium (III) complex stabilized with a tetrathioether macrocyclic ligand - Rh[16aneS(4)-diol](211)At. The purpose of the current study was to evaluate the in vitro and in vivo stability of this complex in comparison to its iodine analog - Rh[16aneS(4)-diol](131)I.
Methods: Rh[16aneS(4)-diol](211)At and Rh[16aneS(4)-diol](131)I complexes were synthesized and purified by HPLC. The stability of both complexes was evaluated in vitro by incubation in phosphate-buffered saline (PBS) and human serum at different temperatures. The in vivo behavior of the two radiohalogenated complexes was assessed by a paired-label biodistribution study in normal Balb/c mice.
Results: Both complexes were synthesized in high yield and purity. Almost no degradation was observed for Rh[16aneS(4)-diol](131)I in PBS over a 72 h incubation. The astatinated analog exhibited good stability in PBS over 14 h. A slow decline in the percentage of intact complex was observed for both tracers in human serum. In the biodistribution study, retention of (211)At in most tissues was higher than that of (131)I at all time points, especially in spleen and lungs. Renal clearance of Rh[16aneS(4)-diol](211)At and Rh[16aneS(4)-diol](131)I predominated, with 84.1 ± 2.3% and 94.6 ± 0.9% of injected dose excreted via the urine at 4 h.
Conclusions: The Rh[16aneS(4)-diol](211)At complex might be useful for constructing prosthetic groups for the astatination of biomolecules and further studies are planned to evaluate this possibility.
Keywords: Astatine-211; Macrocyclic thioether; Prosthetic groups; Radioiodination; Rhodium complexes.
Copyright © 2014 Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.Bioconjug Chem. 2008 Apr;19(4):958-65. doi: 10.1021/bc700413r. Epub 2008 Mar 14. Bioconjug Chem. 2008. PMID: 18338858 Free PMC article.
-
Radioiodinated and astatinated NHC rhodium complexes: synthesis.Nucl Med Biol. 2014 May;41 Suppl:e23-9. doi: 10.1016/j.nucmedbio.2013.12.004. Epub 2013 Dec 12. Nucl Med Biol. 2014. PMID: 24661351
-
211At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment.Nucl Med Biol. 2017 Oct;53:1-8. doi: 10.1016/j.nucmedbio.2017.05.008. Epub 2017 May 25. Nucl Med Biol. 2017. PMID: 28683361
-
Astatine.J Labelled Comp Radiopharm. 2018 Mar;61(3):154-164. doi: 10.1002/jlcr.3573. Epub 2018 Feb 22. J Labelled Comp Radiopharm. 2018. PMID: 29080397 Review.
-
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.Cancer Biother Radiopharm. 2013 Feb;28(1):1-20. doi: 10.1089/cbr.2012.1292. Epub 2012 Oct 17. Cancer Biother Radiopharm. 2013. PMID: 23075373 Free PMC article. Review.
Cited by
-
Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy-Part I.Materials (Basel). 2020 Sep 2;13(17):3875. doi: 10.3390/ma13173875. Materials (Basel). 2020. PMID: 32887308 Free PMC article.
-
Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.J Nucl Med. 2022 Jan;63(1):5-13. doi: 10.2967/jnumed.121.262687. Epub 2021 Sep 9. J Nucl Med. 2022. PMID: 34503958 Free PMC article. Review.
-
Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel). 2024 Jan 8;17(1):76. doi: 10.3390/ph17010076. Pharmaceuticals (Basel). 2024. PMID: 38256909 Free PMC article. Review.
-
Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI Radiopharm Chem. 2024 Oct 4;9(1):69. doi: 10.1186/s41181-024-00298-4. EJNMMI Radiopharm Chem. 2024. PMID: 39365487 Free PMC article. Review.
-
Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy.Acta Biochim Biophys Sin (Shanghai). 2024 Nov 25;57(3):327-343. doi: 10.3724/abbs.2024206. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 39587859 Free PMC article. Review.
References
-
- Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, et al. Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol. 2007;18:1782–1792. - PubMed
-
- Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
-
- Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res. 2006;12:5606–5607. - PubMed
-
- Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32:650–658. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources